Background: Four nonvitamin K antagonist oral anticoagulants (NOACs) are approved for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF).
Introduction
The nonvitamin K antagonist oral anticoagulants (NOACs) include the direct thrombin inhibitor dabigatran and the factor Xa inhibitors (FXaI) apixaban, rivaroxaban, and edoxaban. NOAC efficacy and safety for reducing stroke and systemic embolic events (SEE) in nonvalvular atrial fibrillation (NVAF) was demonstrated in 4 phase 3 trials. [1] [2] [3] [4] NOACs have predictable pharmacokinetic profiles and are administered at fixed dosages without routine laboratory monitoring. 5, 6 Relative to warfarin, NOAC activity is more difficult to assess in acute and interventional settings. Additionally, many clinicians are unfamiliar with management options for NOAC-associated bleeding including hemorrhagic stroke. This article reviews NOAC efficacy and safety for clinicians managing patients who have suffered stroke or transient ischemic attack (TIA).
Efficacy and safety of NOACs for secondary prevention of ischemic stroke
In phase 3 NVAF clinical testing, NOACs were noninferior to warfarin for prevention of stroke or SEE and associated with a 50% risk of intracranial hemorrhage (ICH). [1] [2] [3] [4] These trials included patients with prior stroke or TIA. [1] [2] [3] [4] The rivaroxaban trial enrolled the greatest percentage of patients with prior stroke or SEE (54%). 2 In the edoxaban, dabigatran, and apixaban trials, 28%, 20%, and 19% of patients, respectively, had prior stroke or TIA. 1, 3, 4 In all four trials, stroke rates were consistently higher in patients with a previous cerebrovascular event, irrespective of warfarin or NOAC treatment, reflecting elevated risk within this population. [1] [2] [3] [4] Secondary analyses of rivaroxaban, dabigatran, and apixaban indicated consistent efficacy and safety between patients with and without previous stroke or TIA. [7] [8] [9] Prespecified subgroup analysis for edoxaban demonstrated no differences in safety or efficacy in patients with or without prior stroke or TIA, consistent with other NOACs (Table 1) . 4 Oral anticoagulation is recommended for NVAF patients to prevent stroke recurrence. European, US, and Canadian guidelines recommend NOACs over Vitamin K antagonists (VKA), unless contraindicated, based on net clinical benefit. 6,10-13 NOAC doses are International Journal of Stroke, 11 (7) based on age, renal function, and body weight ( Table 2) . All NOACs are contraindicated in the presence of mechanical heart valves. 10, [13] [14] [15] [16] [17] NOACs interact with the P-glycoprotein (P-gp) transporter and may be contraindicated in patients taking P-gp inhibitors, due to increased bleeding risk, and inducers, due to decreased efficacy. [14] [15] [16] [17] In NOAC-treated patients with post-stroke seizures, phenytoin and carbamazepine-which induce P-gp, should be used with caution. Non-P-gp-interacting alternatives, such as levetiracetam may be preferred in this setting.
Timing of NOAC initiation after stroke
Patients with NVAF who have suffered TIA/ischemic stroke are at high risk for recurrence and require longterm anticoagulation. 5, 18 Stroke risk is high within 90 days of TIA. 19 Anticoagulation timing after ischemic stroke is controversial; acute heparin or warfarin treatment reduces early recurrent stroke, but is offset by comparable increases in symptomatic hemorrhagic transformation (HT) rates. 20, 21 US guidelines recommend anticoagulant initiation or re-initiation within 2 weeks of cardioembolic stroke, except in patients with large infarcts or risk factors for hemorrhage. 22 Following neuroimaging to rule out HT, European guidelines recommend initiating or resuming oral anticoagulants in patients with TIA 3 days after small nondisabling infarcts (National Institutes of Health Stroke Scale (NIHSS) < 8), 5-7 days after moderate infarct (NIHSS 8-16), and 12-14 days after severe infarct (NIHSS > 16). 6 These recommendations are not based on data from clinical trials.
To minimize the potential for HT, phase 3 trials excluded patients with: (a) severe or disabling stroke within 6 months or any stroke within 14 days for dabigatran; (b) severe stroke within 3 months, any stroke within 14 days, or TIA within 3 days for rivaroxaban; (c) stroke within 7 days for apixaban; and (d) any stroke within 30 days for edoxaban. Safety data on early anticoagulation with NOACs following cardioembolic stroke or TIA are limited. Uncontrolled studies of NOAC initiation within 7 days of stroke onset demonstrate the feasibility of this approach, with no symptomatic ICH. 23, 24 In a single-arm, open-label trial of dabigatran initiation within 24 h of minor stroke, there was also no symptomatic HT. 25 Another single-arm, open-label trial of rivaroxaban initiation within 14 days of mild and moderate ischemic stroke also demonstrated no symptomatic HT. 26 In a Japanese registry, which enrolled 1192 patients with NVAF within 7 days of ischemic stroke/TIA, NOAC initiation occurred a median of 4 days from index stroke. 27 No HT was diagnosed prior to discharge in NOAC users. Together, these studies suggest NOAC initiation may be safe within 7 days of ischemic stroke in a subset of patients; however, prospective trials are needed. Open-label studies of dabigatran (clinicaltrials.gov NCT02415855), rivaroxaban (clinicaltrials.gov NCT02129920), and apixaban (clinicaltrials.gov NCT02283294) are ongoing.
Following anticoagulant-associated hemorrhagic stroke, oral anticoagulant therapy can be restarted 4-8 weeks post-event for high cardioembolic risk patients with low risk of new ICH (patients with deep as opposed to lobar location and well-controlled hypertension). 6, [28] [29] [30] There are no published studies of re-anticoagulation after warfarin-or NOAC-related intracranial bleed. Re-anticoagulation with NOACs is theoretically preferable, given the marked reduction in ICH rates relative to warfarin. A study of apixaban vs acetylsalicylic acid and VKA in this patient population is ongoing (clinicaltrials.gov NCT02415400).
Management of stroke in patients taking a NOAC
One advantage of NOACs over VKAs is the lack of requirement for routine laboratory testing. In acute stroke, however, NOAC monitoring is helpful in facilitating thrombolysis or monitoring reversal attempts in cases of intracranial bleeding.
Laboratory monitoring
There is no standard laboratory monitoring test for all NOACs (Table 3 ). Dabigatran can increases activated partial thromboplastin time (aPTT); the effect is variable and assay reagent dependent. 31, 32 Although the effect on aPTT is sensitive and prolonged with therapeutic values of dabigatran, 33 the dose-response relationship is nonlinear. A normal aPTT may not completely exclude some residual anticoagulant activity depending on the assay used. 33, 34 The most accurate coagulation tests for dabigatran are thrombin time (TT), dilute thrombin time (dTT), and ecarin clotting time (ECT); these correlate linearly with dabigatran concentration. 33, 34 Although TT is most sensitive and can rule out clinically significant residual anticoagulant activity at normal TT values, the assay is overly sensitive and may display abnormal values at clinically insignificant dabigatran concentrations. 33 FXaIs prolong prothrombin time (PT) and, to a lesser extent aPTT, with variable anticoagulant-and reagent-dependent effects. 35, 36 With a sensitive thromboplastin reagent, PT measures rivaroxaban concentration with moderate accuracy and is prolonged at peak drug levels. 37 PT prolongation is a much less reliable measure of apixaban 36 and edoxaban 38 levels. Nevertheless, a normal PT cannot exclude clinically relevant anticoagulant activity and PT accuracy is not improved by conversion to international normalized ratio (INR). [36] [37] [38] INR measurements provided by point-of-care testing (POCT; CoaguChek Õ Roche Diagnostics) strongly correlated with rivaroxaban plasma levels; however, significant anticoagulant activity was not detected in 10% of anticoagulated patients. 39 Apixaban levels and POCT results were poorly correlated. 39 There are no POCT data for edoxaban. Anti-Xa activity best correlates with and is linear across a large range of FXaI values. [35] [36] [37] [38] Normal anti-Xa measures using NOAC-specific calibrators and controls can exclude clinically important rivaroxaban, 37 apixaban, 36 and edoxaban 38 concentrations although quantitative anti-Xa measurements are dependent on both the FXaI inhibitor and anti-Xa assay employed. 35 Anti-Xa assays-calibrated for low molecular-weight heparin treatment, rather than NOACs-are available in most centers, although obtaining results in a timely fashion may be challenging.
Thrombolysis
In a meta-analysis of stroke thrombolysis, any warfarin use was associated with increased odds of HT. 40 Thrombolysis is not recommended in warfarin-treated patients with INR > 1.7 in the US 41 and > 1.3 in the UK. 42 Presumably, patients on NOACs who receive tissue plasminogen activator (tPA) have an increased rate of HT; data in this population are sparse. In a pooled analysis of 31 NOAC-treated ischemic stroke patients who received tPA, the fatality rate was 6.5% (two patients). 43 This retrospective series included 15, 10, and 1 patient(s) who received dabigatran, rivaroxaban, and apixaban, respectively. 43 The mean elapsed time between last NOAC dose and tPA administration was 12 h (range 4-28 h). 43 Specialized coagulation tests may help select patients with undetectable or negligible anticoagulant activity who can safely be thrombolyzed. An approach to thrombolysis selection in dabigatran treated patients using a calibrated TT and/or normal aPTT has been reported. 44 No prospective trials have assessed anti-Xa levels after acute ischemic stroke in FXaI-prescribed patients. US guidelines recommend against intravenous tPA in patients taking NOACs unless an adequately sensitive laboratory assay (TT, ECT, or anti-Xa assay where appropriate) is within normal range or the patient has not received a dose of these agents for-> 48 h. 41, 45 In large vessel occlusion cases, intra-arterial clot retrieval procedures are standard of care and the authors suggest withholding bridging thrombolytic therapy in these cases. 46 
Management of bleeding and ICH
American College of Chest Physicians guidelines recommend prothrombin complex concentrates (PCC) over fresh frozen plasma for life-threatening bleeds associated with VKA anticoagulation. 47 A recent randomized trial demonstrated that PCCs normalize INR faster than fresh frozen plasma in VKA-associated ICH. 48 Use of PCC is also associated with less hematoma expansion and a trend toward reduced mortality without increased risk of thrombotic events. One meta-analysis of reversal studies reported a 10.6% overall mean mortality rate following PCC administration. 49 However, despite reversal, poor outcomes are still common. In an open-label warfarin-associated ICH study, PCC was associated with a 43% mortality rate, despite INR normalization in 71.8% of patients within 1 h of treatment. 50 Unlike warfarin, NOACs are fast-acting with relatively short half-lives. For major bleeds, including ICH, rapid restoration of normal hemostasis is prudent (Table 3) . Tactics for achieving hemostasis have focused on supplementing coagulation factors, or International Journal of Stroke, 11 (7) more recently, on NOAC neutralization with direct reversal agents. NOAC reversal with PCC has been studied in vitro, animal models, and in healthy volunteers via coagulation parameter measurements. 51 While overwhelming the NOAC with precursor factors contained in PCC is biologically plausible, effects on patient bleeding and clinical outcomes are unproven.
Dabigatran reversal with activated factor VII (FVIIa), 4-factor PCC, aPCC or FEIBA TM (Factor Eight Inhibitor Bypassing Activity), and the specific antidote idarucizumab has been evaluated. Ex vivo administration of FVIIa in healthy volunteers receiving dabigatran improved endogenous thrombin potential, a surrogate coagulation marker; further, activated PCCs were superior to unactivated 4-factor PCCs for dabigatran reversal. 52 Another trial revealed no effect of 4factor PCCs on aPTT, TT, or ECT. 53 Idarucizumab, a human antibody fragment that binds and removes dabigatran from the circulation, is the first specific reversal agent approved in the US, Canada, Australia, and Europe. [54] [55] [56] [57] In an interim analysis of 90 patients requiring reversal due to bleeding or a need for urgent surgery, administration of two 2.5 -g doses of idarucizumab within 15 min rapidly corrected aPTT, dTT, and ECT. 58 In healthy volunteers administered rivaroxaban, 4factor PCCs corrected PT, which is qualitatively but not quantitatively prolonged by FXaIs. 53 Other studies demonstrated partial correction of some coagulation parameters by PCCs in healthy volunteers taking rivaroxaban, but not anti-Xa activity. 59, 60 In edoxaban-treated volunteers, 4-factor PCCs corrected coagulation parameters and reduced bleeding after punch biopsy; coagulation parameter improvement by 4-factor PCC was dose-dependent, with greatest correction from PCC 50 IU/kg. 61 In ex vivo studies of rivaroxaban-treated volunteers, activated PCCs corrected some coagulation parameters, not including anti-Xa activity. 52, 59 Andexanet alfa (Portola Pharmaceuticals, San Francisco, USA), a FXa analogue without anticoagulant activity that binds and sequesters FXaI, is currently being evaluated in patients with acute major bleeding (NCT02329327). Andexanet alfa rapidly reversed rivaroxaban, apixaban, edoxaban, and enoxaparin effects in phase 2 studies. 62 The ANNEXA-A and ANNEXA-R trials showed prompt reversal of anticoagulant activity as measured by anti-Xa activity and thrombin generation of apixaban and rivaroxaban, respectively, in healthy volunteers. 63 As andexanet alfa has a short half-life, coagulation parameters and unbound serum NOAC concentrations rebounded after initial reversal 63 ; necessitating a bolus followed by infusion protocol. 63 A nonspecific reversal agent, PER977 that electrostatically binds heparin, low molecular weight heparin and all commercially available NOACs is being investigated. A single intravenous dose restores baseline hemostasis within 10-30 min in volunteers administered 60 mg edoxaban. 64 Studies of PER977 in healthy volunteers exposed to edoxaban are ongoing (clinicaltrials.gov NCT02207257).
Conclusion
NOACs are effective for stroke prevention in NVAF patients and are associated with marked reductions in ICH. They demonstrate consistent benefits in patients with and without prior ischemic stroke/TIA. Thus, NOACs are recognized as first-line options for stroke prevention in NVAF patients.
Management of patients taking NOACs and initiation of NOACs in acute and subacute phases of ischemic and hemorrhagic stroke present particular challenges. There is little evidence guiding management in these situations; empiric decisions are ideally made by stroke specialists. Sensitive and specific tests to detect and quantify NOAC serum levels and specific reversal agents will allow development of effective protocols to manage ischemic and hemorrhagic stroke.
